Allspring Global Investments Holdings LLC Purchases 1,474 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Allspring Global Investments Holdings LLC grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,751 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,474 shares during the period. Allspring Global Investments Holdings LLC owned about 0.11% of ANI Pharmaceuticals worth $1,449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in shares of ANI Pharmaceuticals by 10.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 131,156 shares of the specialty pharmaceutical company’s stock valued at $8,352,000 after buying an additional 12,865 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after acquiring an additional 200 shares during the period. Sequoia Financial Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $600,000. Simplicity Wealth LLC raised its position in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 227 shares during the period. Finally, Boston Partners acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $606,000. 76.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on ANIP. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Truist Financial cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $82.75.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Muthusamy Shanmugam sold 11,000 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the completion of the sale, the chief operating officer now directly owns 671,620 shares of the company’s stock, valued at approximately $42,567,275.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,007 shares of company stock worth $4,091,535. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.1 %

Shares of ANI Pharmaceuticals stock opened at $63.03 on Wednesday. The firm has a market cap of $1.32 billion, a PE ratio of 39.39 and a beta of 0.75. The business’s 50 day simple moving average is $62.08 and its 200 day simple moving average is $63.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same period last year, the company earned $1.06 earnings per share. The firm’s revenue was up 18.5% compared to the same quarter last year. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.